Drugs / Sodium Glycididazole
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06667622 | May 2024 → Jan 2026 overdue | chemotherapy-induced toxicity | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02721550 | Aug 2016 → Jun 2018 | neoplasm of esophagus | Shandong Cancer Hospital and Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02721576 | Jul 2016 → Jun 2018 | carcinoma of esophagus | Shandong Cancer Hospital and Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00642239 | Apr → Dec 2008 | carcinoma of esophagus | Shandong Luye Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02721563 Comparator | Feb 2016 → Jun 2018 | neoplasm of esophagus | Shandong Cancer Hospital and Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Glycididazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00642239 ↗ |
| Known as | CMNa | “PURPOSE: To evaluate the efficacy and safety of the radiosensitizer-sodium glycididazole (CMNa) combined with definitive concurrent chemoradiotherapy (CCRT) versus CCRT alone...” PMID 42022351 ↗ Feb 2026 |
| Modality | Small molecule | — CHEMBL4303058 ↗ |
| Route | Intravenous | “Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip” NCT00642239 ↗ |